Know Cancer

forgot password

Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study

Phase 1/Phase 2
18 Years
75 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study

A phase II trial with 142 patients demonstrated that therapy with docetaxel plus epirubicin
is highly active first-line therapy for metastatic breast cancer, with acceptable toxicity
profile. Recently initial therapy of metastatic breast cancer with paclitaxel plus
bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel
alone. This study will evaluate the efficacy and toxicity of docetaxel-epirubicin
combination plus bevacizumab as first line treatment in patients with metastatic and HER2
negative breast cancer. Furthermore, the efficacy of the combination therapy will be
correlated with the presence of circulating tumor cells (CTCs) in this population.

Inclusion Criteria:

- Histologically- or cytologically- confirmed metastatic breast adenocarcinoma

- No HER2 overexpression or gene amplification

- No previous therapy for metastatic breast cancer is allowed

- Age 18-75 years

- At least 12 months interval since prior adjuvant therapy with taxanes and/or

- Measurable disease as defined by the presence of at least one measurable lesion
(except bone metastases, ascites or pleural effusions)

- Performance status (WHO) 0-2

- Adequate liver (serum bilirubin <1.5 times the upper normal limit, AST and ALT <2.5
times the upper normal limit in the absence of demonstrable liver metastases, or <5
times the UNL in the presence of liver metastases)

- Adequate renal function (serum creatinine <1.5 times the upper normal limit

- Adequate bone marrow function (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x 109

- Written informed consent

Exclusion Criteria:

- Active infection

- Brain metastases

- History of significant cardiac disease (unstable angina, congestive heart failure,
myocardial infarction within the previous 6 months, ventricular arrhythmias)

- History of stroke

- Anticoagulation therapy (except of low dose aspirin <325mg)

- Other invasive malignancy except nonmelanoma skin cancer

- Psychiatric illness or social situation that would preclude study compliance

- Pregnant or lactating women

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Response Rate

Outcome Time Frame:

Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)

Safety Issue:


Principal Investigator

Dimitris Mavrudis, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital of Crete, Dep of Medical Oncology


Greece: National Organization of Medicines

Study ID:




Start Date:

May 2008

Completion Date:

June 2010

Related Keywords:

  • Breast Cancer
  • breast cancer
  • chemotherapy
  • biological therapy
  • Breast Neoplasms